Video

Dr. Zhang on adaptive phase 3 trial of nivolumab, ipilimumab, and cabozantinib in kidney cancer

Tian Zhang, MD, discusses the ongoing phase 3 PDIGREE study (NCT03793166) exploring immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy) followed by nivolumab or nivolumab with cabozantinib (Cabometyx) for patients with intermediate/poor-risk metastatic clear cell renal cell carcinoma

Zhang, who is an associate professor at UT Southwestern Medical Center, was interviewed during the 2021 Kidney cancer research summit in Philadelphia, Pennsylvania.

Related Videos
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Related Content
© 2025 MJH Life Sciences

All rights reserved.